Transcript

Finding relief: Craig's story with bipolar II depression

(DESCRIPTION)

Video begins with a still of Craig with an opaque overlay. Copy builds and disappears on screen. ITCI logo appears on the bottom right of the screen.

(ON SCREEN TEXT)

Craig's Story with Bipolar II Depression

[ITCI logo]

The patient and healthcare provider in this video are sharing their individual experiences. They have been compensated for their time. This resource is brought to you by Intra‑Cellular Therapies.

(DESCRIPTION)

Screen cuts to a canvas and painting tools. Craig is painting on a canvas.

(Craig)

In my twenties, I started feeling just a little bouts of depression. But by my mid-thirties, it was so monumental, I felt like I could no longer function day to day or complete basic tasks. It continued to get worse into my forties. That's when with my mother by my side, I was diagnosed with bipolar II depression.

(DESCRIPTION)

Camera cuts to Craig talking to the camera with on screen text in the bottom left.

(ON SCREEN TEXT)

Craig

Patient Advocate with Bipolar II Depression

(Craig)

For a few years, I worked with my healthcare team to identify options that might work for me.

(DESCRIPTION)

On screen text disappears and camera cuts to Craig painting in a forest.

(Craig)

I stayed proactive and didn't find the success I was looking for. Then I heard a TV commercial where the announcer said for the treatment of bipolar II depression. I immediately got in touch with my psychiatric nurse practitioner to ask about the treatment.

(DESCRIPTION)

Camera cuts to Deborah, a psychiatric nurse practitioner, speaking to the camera. On screen text appears in the bottom left corner and then disappears.

(ON SCREEN TEXT)

Deborah

Psychiatric Nurse Practitioner

(Deborah)

I see a lot of patients like Craig who are suffering from bipolar I or II depression. Bipolar depression is part of a larger mental health condition called bipolar disorder, which causes extreme changes in mood and behavior.

(DESCRIPTION)

Craig is outside painting on a canvas while Deborah provides voiceover. On screen text disappears.

(Deborah)

Craig's diagnosis of bipolar II depression means he tends to experience longer depressive episodes that can be more severe than with bipolar I, while not experiencing debilitating bouts of mania. This can make bipolar II hard to diagnose as it can be frequently confused with major depressive disorder.

(DESCRIPTION)

Deborah is in her office, working on her computer. On screen text appears at the bottom of the screen and the CAPLYTA logo is in the bottom right corner.

(ON SCREEN TEXT)

CAPLYTA is not approved for dementia-related psychosis.

[CAPLYTA logo] FOR BIPOLAR I & II DEPRESSION

(Deborah)

CAPLYTA is a prescription medication used to treat depressive episodes associated with bipolar I or bipolar II depression in adults. For patients experiencing bipolar I or bipolar II depression, I always consider CAPLYTA as an option. I like the efficacy and safety profile and that weight gain and movement disorders such as akathisia were similar to placebo in short-term clinical trials.

(DESCRIPTION)

The camera cuts to a shot of the patient brochure. Previous on screen text and CAPLYTA logo remain.

(ON SCREEN TEXT)

CAPLYTA is not approved for dementia-related psychosis.

[CAPLYTA logo] FOR BIPOLAR I & II DEPRESSION

(Deborah)

However, CAPLYTA is not right for everyone. CAPLYTA is not approved for dementia-related psychosis as it can increase the risk of death or stroke.

(DESCRIPTION)

Camera cuts to Craig painting in the forest. Previous on screen text disappears. CAPLYTA logo remains in the bottom right corner.

(ON SCREEN TEXT)

[CAPLYTA logo] FOR BIPOLAR I & II DEPRESSION

(Craig)

I went to see my nurse practitioner and mentioned the ad for CAPLYTA. She explained to me that CAPLYTA was a once-a-day capsule, believed to work by affecting the chemicals in the brain involved in mood. I like that CAPLYTA was approved to help reduce my symptoms of bipolar depression, specifically, bipolar II depression. It meant a lot to me that after reviewing the side effect profile, movement disorders and weight gain were not common. I also thought it was convenient that CAPLYTA was a once-a-day pill I could take with or without food. And without having to build up to the appropriate dose.

(DESCRIPTION)

Camera cuts to Deborah in her office and then speaking to the camera. New on screen text appears at the bottom of the screen. CAPLYTA logo remains in the bottom right corner.

(ON SCREEN TEXT)

High cholesterol and weight gain may occur, as can high blood sugar, which may be fatal. Monitoring is recommended.

[CAPLYTA logo] FOR BIPOLAR I & II DEPRESSION

(Deborah)

While considering CAPLYTA as a treatment option for Craig, we reviewed the efficacy and safety data from the bipolar depression clinical trials. Craig was excited that in the short‑ and long-term trials, most people who took CAPLYTA did not gain weight.

(DESCRIPTION)

Camera cuts to Deborah in her office talking with Craig and showing him the patient brochure. Previous on screen text disappears. CAPLYTA logo remains in the bottom right corner.

(ON SCREEN TEXT)

[CAPLYTA logo] FOR BIPOLAR I & II DEPRESSION

(Deborah)

I told Craig that after 6 months, the average weight change for people taking CAPLYTA in the clinical trial was -0.02 lbs. But every patient responds differently and medications used to treat bipolar depression may cause weight gain, high cholesterol, and high blood sugar. I always monitor my patients while they're taking these types of medications. Before I prescribe CAPLYTA, I carefully listen to my patients and answer all their questions.

(DESCRIPTION)

Camera cuts to Deborah talking to the camera, with periodic shots of her office. On screen text appears at the bottom of the screen. CAPLYTA logo remains in the bottom right corner.

(ON SCREEN TEXT)

CAPLYTA can increase the risk of sudden mood changes, behaviors, or suicidal thoughts. Call your healthcare provider right away if you experience these symptoms.

[CAPLYTA logo] FOR BIPOLAR I & II DEPRESSION

(Deborah)

I assure them that I have experienced treating patients with CAPLYTA and that it is approved to provide significant relief from bipolar depression symptoms. I tell them that they may see improvement in the first week with significant relief by 6 weeks. Of course, everyone's experience may be different and every patient should work with their healthcare provider to determine what treatment is the best choice for them.

(DESCRIPTION)

Camera cuts to Deborah working in her office. Old on screen text disappears and new on screen text appears in its place. CAPLYTA logo remains in the bottom right corner.

(ON SCREEN TEXT)

Report fever, stiff muscles or confusion, which may be life-threatening, or uncontrollable muscle movements, which may be permanent.

[CAPLYTA logo] FOR BIPOLAR I & II DEPRESSION

(Deborah)

When a patient and I have decided that CAPLYTA is the best choice for them, I make sure they understand that antidepressants may increase the risk of suicidal thoughts and to call me immediately if they experience these thoughts or have any sudden mood changes or behaviours. Also, I make sure that they know to call me if they experience fever, confusion, stiffness, or uncontrollable muscle movements which may be life-threatening or permanent. Please be sure to listen to the Important Safety Information at the end of this video for more information about CAPLYTA.

(DESCRIPTION)

Craig is with friends and eating dinner. Previous on screen text disappears. CAPLYTA logo remains in the bottom right corner.

(ON SCREEN TEXT)

[CAPLYTA logo] FOR BIPOLAR I & II DEPRESSION

(Craig)

My nurse practitioner was straightforward with me. She kept my expectations in check. She said let's try it and see how it goes. Before I started CAPLYTA, I told my healthcare provider about all the medical conditions I had and all the medications I was taking. My nurse practitioner and I went over the potential benefits and risks of treatment. Including the most common side effects such as sleepiness, dizziness, nausea, and dry mouth. In the beginning, I experienced fatigue for about a week. And I've been relieved I haven't experienced any weight gain so far while taking CAPLYTA.

(DESCRIPTION)

Camera cuts to Deborah in her office, hanging a painting. CAPLYTA logo remains in the bottom right corner.

(ON SCREEN TEXT)

[CAPLYTA logo] FOR BIPOLAR I & II DEPRESSION

(Deborah)

I often prescribe CAPLYTA as a treatment for my bipolar I and II depression patients. I feel that the combined efficacy and safety along with the convenient dosing strategy makes CAPLYTA an excellent choice for Craig and I have certainly seen a difference.

(DESCRIPTION)

Camera cuts between Craig with his friends and speaking to the camera. On screen text appears at the bottom of the screen and CAPLYTA logo remains in the bottom right corner.

(ON SCREEN TEXT)

Individual results may vary.

[CAPLYTA logo] FOR BIPOLAR I & II DEPRESSION

(Craig)

The symptom relief I experience with CAPLYTA has changed things for me. I feel lighter. I'm glad that I no longer feel like I have to fear my condition. Because of the improvement in my symptoms, I feel like I can better manage. CAPLYTA has helped me rediscover this light.

(DESCRIPTION)

Screen goes white. Previous on screen text disappears and Important Safety Information appears on screen. The CAPLYTA logo remains in the bottom right corner and the ITCI logo is in the top right corner. Important Safety Information begins scrolling as it's read on voiceover.

(ON SCREEN TEXT)

[ITCI logo]

[CAPLYTA logo] FOR BIPOLAR I & II DEPRESSION

Important Safety Information

Medicines like CAPLYTA can raise the risk of death in elderly people who have lost touch with reality (psychosis) due to confusion and memory loss (dementia). CAPLYTA is not approved for treating people with dementia-related psychosis.

CAPLYTA and antidepressant medicines may increase suicidal thoughts and actions in some children, adolescents, and young adults especially within the first few months of treatment or when the dose is changed. Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Patients and their families or caregivers should watch for new or worsening depression symptoms, especially sudden changes in mood, behaviors, thoughts, or feelings. This is very important when CAPLYTA or an antidepressant medicine is started or when the dose is changed. Report any change in these symptoms to your healthcare provider immediately.

Do not take CAPLYTA if you are allergic to any of its ingredients. Get emergency medical help if you are having an allergic reaction (e.g., rash, itching, hives, swelling of the tongue, lip, face, or throat).

CAPLYTA may cause serious side effects, including:

Stroke (cerebrovascular problems) in elderly people with dementia‑related psychosis that can lead to death.
Neuroleptic malignant syndrome (NMS): high fever, confusion, changes in your breathing, heart rate, and blood pressure, stiff muscles, and increased sweating; these may be symptoms of a rare but potentially fatal condition. Contact your healthcare provider or go to the emergency room if you experience signs and symptoms of NMS.
Uncontrolled body movements (tardive dyskinesia, TD) in your face, tongue, or other body parts. TD may not go away, even if you stop taking CAPLYTA. It may also occur after you stop taking CAPLYTA.
Problems with your metabolism including high blood sugar, diabetes, increased fat (cholesterol and triglyceride) levels in your blood and weight gain. Your healthcare provider should check your blood sugar, fat levels and weight before you start and during your treatment with CAPLYTA. Extremely high blood sugar levels can lead to coma or death. Call your healthcare provider if you have any of the following symptoms of high blood sugar: feeling very thirsty, hungry, sick to your stomach, needing to urinate more than usual, weak/tired, or confused, or your breath smells fruity.
Low white blood cell count. Your healthcare provider may do blood tests during the first few months of treatment with CAPLYTA.
Decreased blood pressure (orthostatic hypotension). You may feel lightheaded, dizzy, or faint when you rise too quickly from a sitting or lying position.
Falls. CAPLYTA may make you sleepy or dizzy, may cause a decrease in your blood pressure when changing position (orthostatic hypotension), and can slow your thinking and motor skills which may lead to falls that can cause broken bones or other injuries.
Seizures (convulsions).
Sleepiness, drowsiness, feeling tired, difficulty thinking and doing normal activities. Until you know how CAPLYTA affects you, do not drive, operate heavy machinery, or do other dangerous activities.
Problems controlling your body temperature so that you feel too warm. Avoid getting overheated or dehydrated while taking CAPLYTA.
Difficulty swallowing that can cause food or liquid to get into the lungs.

The most common side effects of CAPLYTA include sleepiness, dizziness, nausea, and dry mouth.

These are not all the possible side effects of CAPLYTA. Tell your healthcare provider if you have or have had heart problems or a stroke, high or low blood pressure, diabetes, or high blood sugar, problems with cholesterol, have or have had seizures (convulsions), kidney or liver problems, or a low white blood cell count. CAPLYTA may cause fertility problems in females and males. You should notify your healthcare provider if you become pregnant or intend to become pregnant while taking CAPLYTA. CAPLYTA may cause abnormal involuntary movements and/or withdrawal symptoms in newborn babies exposed to CAPLYTA during the third trimester. Talk to your healthcare provider if you breastfeed or are planning to breastfeed as CAPLYTA passes into breast milk. Tell your healthcare provider about all the medicines you're taking. CAPLYTA may affect the way other medicines work, and other medicines may affect how CAPLYTA works, causing possible serious side effects. Do not start or stop any medicines while taking CAPLYTA without talking to your healthcare provider. You are encouraged to report negative side effects of prescription drugs. Contact Intra‑Cellular Therapies, Inc. at 1‑888‑611‑4824 or FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch.

CAPLYTA is available in 10.5 mg, 21 mg, and 42 mg capsules.

(DESCRIPTION)

Previous on screen text disappears and the screen becomes blue. The CAPLYTA logo is in the middle of the screen. There is legal language in the bottom left corner and the ITCI logo is in the bottom right corner.

[CAPLYTA logo]

[ITCI logo]